hydroxyurea has been researched along with Acute Hemolytic Transfusion Reaction in 28 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We previously reported the use of hydroxyurea/phlebotomy as an alternative to transfusions to reduce the risk of secondary stroke and improve management of iron overload in 35 children with SCA." | 7.77 | Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. ( Greenway, A; Thornburg, CD; Ware, RE, 2011) |
| " The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates." | 6.78 | Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. ( Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA, 2013) |
| "Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated." | 6.77 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). ( Helms, RW; Ware, RE, 2012) |
| "Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea (TWiTCH) trial is a randomized, open-label comparison of hydroxycarbamide (also termed hydroxyurea) versus continued chronic transfusion therapy for primary stroke prevention in patients with sickle cell anaemia (SCA) and abnormal TCD." | 5.22 | Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. ( Aygun, B; Cohen, AR; Davis, BR; Fuh, B; Imran, H; Luchtman-Jones, L; Pressel, SL; Schultz, WH; Thompson, AA; Ware, RE; Wood, JC, 2016) |
| " We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients." | 5.20 | Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. ( Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC, 2015) |
| "We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years." | 5.17 | Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. ( Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y, 2013) |
| " The first two trials addressed the use of chronic transfusion to prevent primary stroke; the third utilized the drug hydroxycarbamide (hydroxyurea) and phlebotomy to prevent both recurrent (secondary) stroke and iron overload in patients who had already experienced an initial stroke." | 4.89 | Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Dwan, K; Wang, WC, 2013) |
| " We previously reported the use of hydroxyurea/phlebotomy as an alternative to transfusions to reduce the risk of secondary stroke and improve management of iron overload in 35 children with SCA." | 3.77 | Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. ( Greenway, A; Thornburg, CD; Ware, RE, 2011) |
| " The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates." | 2.78 | Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. ( Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA, 2013) |
| "Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated." | 2.77 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). ( Helms, RW; Ware, RE, 2012) |
| "Hydroxyurea (HU) has demonstrated promising outcomes; additionally, thalidomide has also shown improvement in hemoglobin (Hb) levels for patients with β-thalassemia in some studies." | 1.72 | Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia. ( Adil, SO; Ansari, AH; Ansari, I; Ansari, SH; Ansari, UH; Farooq, F; Hussain, Z; Khawaja, S; Masqati, NU; Sattar, A; Wasim, M; Zohaib, M, 2022) |
| "Hydroxyurea has enhanced the treatment for children with sickle cell anemia." | 1.37 | Impact of hydroxyurea on perioperative management and outcomes in children with sickle cell anemia. ( Calatroni, A; Hayashi, M; Herzberg, B; Rice, HE; Ross, AK; Thornburg, C, 2011) |
| "A 70-year-old man with primary myelofibrosis was treated with hydroxycarbamide and blood transfusions." | 1.31 | [Diagnostic image (117). A man with frequent blood transfusion and blister on his fingers. A form of porpheria cutanea tarda caused by excess iron]. ( Jonkhoff, AR; van der Valk, P; Zweegman, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 17 (60.71) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Ansari, SH | 1 |
| Ansari, I | 1 |
| Wasim, M | 1 |
| Sattar, A | 1 |
| Khawaja, S | 1 |
| Zohaib, M | 1 |
| Hussain, Z | 1 |
| Adil, SO | 1 |
| Ansari, AH | 1 |
| Ansari, UH | 1 |
| Farooq, F | 1 |
| Masqati, NU | 1 |
| Srivastava, K | 1 |
| Albasri, J | 1 |
| Alsuhaibani, OM | 1 |
| Aljasem, HA | 1 |
| Bueno, MU | 1 |
| Antonacci, T | 1 |
| Branch, DR | 1 |
| Denomme, GA | 1 |
| Flegel, WA | 1 |
| Ghosh, K | 2 |
| Sheth, S | 1 |
| Licursi, M | 1 |
| Bhatia, M | 1 |
| Alvarez, O | 1 |
| Yovetich, NA | 1 |
| Scott, JP | 1 |
| Owen, W | 1 |
| Miller, ST | 1 |
| Schultz, W | 1 |
| Lockhart, A | 1 |
| Aygun, B | 2 |
| Flanagan, J | 1 |
| Bonner, M | 1 |
| Mueller, BU | 1 |
| Ware, RE | 5 |
| Vichinsky, E | 1 |
| Torres, M | 1 |
| Minniti, CP | 1 |
| Barrette, S | 1 |
| Habr, D | 1 |
| Zhang, Y | 1 |
| Files, B | 1 |
| Wang, WC | 1 |
| Dwan, K | 1 |
| El-Beshlawy, A | 1 |
| El-Ghamrawy, M | 1 |
| EL-Ela, MA | 1 |
| Said, F | 1 |
| Adolf, S | 1 |
| Abdel-Razek, AR | 1 |
| Magdy, RI | 1 |
| Abdel-Salam, A | 1 |
| Tantawy, AA | 1 |
| Adly, AA | 1 |
| Ismail, EA | 1 |
| Darwish, YW | 1 |
| Ali Zedan, M | 1 |
| Smith-Whitley, K | 1 |
| Wood, JC | 2 |
| Pressel, S | 1 |
| Rogers, ZR | 2 |
| Odame, I | 1 |
| Kwiatkowski, JL | 1 |
| Lee, MT | 1 |
| Owen, WC | 1 |
| Cohen, AR | 2 |
| St Pierre, T | 1 |
| Heeney, MM | 1 |
| Schultz, WH | 2 |
| Davis, BR | 2 |
| Pressel, SL | 1 |
| Imran, H | 1 |
| Luchtman-Jones, L | 1 |
| Thompson, AA | 1 |
| Fuh, B | 1 |
| Meier, ER | 1 |
| Rampersad, A | 1 |
| Ileri, T | 1 |
| Azik, F | 1 |
| Ertem, M | 1 |
| Uysal, Z | 1 |
| Gozdasoglu, S | 1 |
| Carmel, R | 1 |
| Bellevue, R | 1 |
| Kelman, Z | 1 |
| Greenway, A | 1 |
| Thornburg, CD | 1 |
| Hayashi, M | 1 |
| Calatroni, A | 1 |
| Herzberg, B | 1 |
| Ross, AK | 1 |
| Rice, HE | 1 |
| Thornburg, C | 1 |
| Karimi, M | 1 |
| Haghpanah, S | 1 |
| Farhadi, A | 1 |
| Yavarian, M | 1 |
| Helms, RW | 1 |
| Brousse, V | 1 |
| Gandhi, S | 1 |
| de Montalembert, M | 1 |
| Height, S | 1 |
| Dick, MC | 1 |
| O'Driscoll, S | 1 |
| Abihsera, G | 1 |
| Rees, DC | 1 |
| Zweegman, S | 1 |
| van der Valk, P | 1 |
| Jonkhoff, AR | 1 |
| Buchanan, GR | 1 |
| Gaziev, J | 1 |
| Sodani, P | 1 |
| Polchi, P | 1 |
| Andreani, M | 1 |
| Lucarelli, G | 1 |
| Fathallah, H | 1 |
| Sutton, M | 1 |
| Atweh, GF | 1 |
| Styles, LA | 1 |
| Vichinsky, EP | 2 |
| Ballas, SK | 1 |
| Reed, W | 1 |
| Ebbe, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Combination of Hydroxyurea and Low-dose Thalidomide on Hemoglobin Synthesis in Thalassemia Patients[NCT05132270] | Phase 2/Phase 3 | 135 participants (Actual) | Interventional | 2020-01-01 | Completed | ||
| Stroke With Transfusions Changing to Hydroxyurea[NCT00122980] | Phase 3 | 134 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to The study has been stopped due to safety and futility concerns.) | ||
| Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell[NCT02561312] | 9 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Barthel Index is a measure of activities of daily living (ADL) and assesses the degree of disability in a particular participant. The index records indicators of independence in terms of the disability caused by impairments, such as those that may be sequelae of stroke. The index was used as a record of what the participant did, not as a record of what the participant could do. Barthel scores range from 0 to 100, with higher scores indicating greater independence in daily living activities (caring for oneself). (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | -0.33 |
| Transfusion/Chelation | -0.53 |
(NCT00122980)
Timeframe: Baseline to end of study participation (up to 136 weeks)
| Intervention | cm (Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | 4.40 |
| Transfusion/Chelation | 6.61 |
(NCT00122980)
Timeframe: baseline to end of study participation (up to 136 weeks)
| Intervention | kg (Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | 3.83 |
| Transfusion/Chelation | 6.36 |
LIC change-from-baseline is the second component of the composite primary endpoint. LIC was measured by quantitative liver biopsy at baseline and at 30 months or exit from the study.LIC values were transformed into Log10 values prior to computing the change from baseline. (NCT00122980)
Timeframe: Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)
| Intervention | mg ferritin/gram dry weight liver (Log Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | -0.006 |
| Transfusion/Chelation | -0.120 |
This test is designed to assess both broad and narrow cognitive abilities in children age 4 years and above as well as to measure major aspects of academic achievement in persons aged 2-90 years. Higher scores mean better abilities/achievements. Scaled scores range from 0-100. (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | 1.829 |
| Transfusion/Chelation | -2.487 |
Secondary stroke is the first component of the composite primary endpoint and considers the number of participants with recurrent secondary stroke events during 30 months of treatment. Stroke was defined as any clinical event with brain injury due to vascular disease. All neurological events underwent formal stroke adjudication. (NCT00122980)
Timeframe: Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)
| Intervention | participants (Number) | |
|---|---|---|
| Stroke | No Stroke | |
| Hydroxyurea/Phlebotomy | 7 | 60 |
| Transfusion/Chelation | 0 | 66 |
The PedsQLTM Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. It has a Likert 5-points scale (never to almost always) which were transformed to a 0 to 100 scale based on the PedsQL scoring algorithms, higher scores indicating better quality of life characteristics. (NCT00122980)
Timeframe: Baseline, midpoint (week 64), and study exit (up to 30 months of treatment)
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Midpoint: Emotional Functioning Score (n=47, 57) | Exit: Emotional Functioning Score (n=55, 54) | Midpoint: Physical Functioning Score (n=47, 57) | Exit: Physical Functioning Score (n=55, 54) | Midpoint: School Functioning Score (n=47, 57) | Exit: School Functioning Score (n=55, 53) | Midpoint: Social Functioning Score (n=46, 57) | Exit: Social Functioning Score (n=54, 54) | Midpoint: Total Functioning Score (n=47, 57) | Exit: Total Functioning Score (n=55, 54) | Midpoint: Psychosocial Health Summary (n=47, 57) | Exit: Psychosocial Health Summary Score (n=57, 54) | |
| Hydroxyurea/Phlebotomy | 1.06 | 3.82 | 0.46 | 3.41 | -1.03 | 1.76 | 2.39 | 3.13 | 0.35 | 2.90 | 0.28 | 2.65 |
| Transfusion/Chelation | 3.51 | 3.80 | 3.18 | 2.03 | 4.56 | 2.74 | 1.84 | 2.87 | 3.26 | 2.62 | 3.30 | 2.93 |
The PedsQL(TM) Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. It has a Likert 5-points scale (never to almost always) which were transformed to a 0 to 100 scale based on the PedsQL scoring algorithms, higher scores indicating better quality of life characteristics. (NCT00122980)
Timeframe: Baseline, mid-point (week 64), and study exit after up to 30-month treatment period (due to study termination)
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mid-point: Emotional Functioning Score (n=43,54) | Exit: Emotional Functioning Score (n=52, 54) | Mid-point: Physical Functioning Score (n=43,64) | Exit: Physical Functioning Score (n=53, 54) | Mid-point: School Functioning (n=43, 54) | Exit: School Functioning (n=51,53) | Mid-point : Social Functioning Score (n=42, 54) | Exit : Social Functioning Score (n=53, 54) | Mid-point: Total Functioning Score (n=43, 54) | Exit: Total Functioning Score (n=53, 54) | Mid-point: Psychosocial Health Summary (n=43,54) | Exit: Psychosocial Health Summary (n=53, 54) | |
| Hydroxyurea/Phlebotomy | -0.99 | -1.25 | -1.71 | 2.27 | 3.14 | -0.29 | 3.69 | 2.67 | 0.39 | 1.13 | 1.61 | 0.33 |
| Transfusion/Chelation | 5.56 | 5.65 | -0.57 | -0.98 | -3.34 | 2.83 | -0.35 | -1.11 | 0.20 | 1.09 | 0.59 | 2.11 |
This test is designed to assess both broad and narrow cognitive abilities in children age 4 years and above as well as to measure major aspects of academic achievement in persons aged 2-90 years. Scaled scores range from 0-100. Higher scores mean better abilities/achievements. (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| General intellectual ability (n=33, 35) | Processing speed (n=35, 33) | Working memory (n=33, 34) | Broad attention (n=31, 33) | Executive processes (n=32, 33) | Broad reading (n=34, 33) | Broad math (n=34, 33) | |
| Hydroxyurea/Phlebotomy | -1.64 | -0.80 | -7.67 | -4.36 | -0.72 | -0.29 | -3.53 |
| Transfusion/Chelation | -3.00 | 2.06 | -2.65 | -0.49 | -1.15 | -0.94 | -5.76 |
8 reviews available for hydroxyurea and Acute Hemolytic Transfusion Reaction
| Article | Year |
|---|---|
Sickle cell disease: time for a closer look at treatment options?
Topics: Africa; Anemia, Sickle Cell; Brain Damage, Chronic; Cardiovascular Diseases; Chelation Therapy; Chro | 2013 |
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Early Termination of Clinical Trials; Humans; Hydroxy | 2013 |
Reproductive issues in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Female; Fertility; Humans; Hydroxyurea; Infertility, Femal | 2014 |
Pediatric sickle cell disease: past successes and future challenges.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Cerebrovascular Circulation; Child; Child, Pre | 2017 |
Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Combined Modality Therapy; Drug Approval; Drug Evaluation | 2005 |
New therapies and approaches to transfusion in sickle cell disease in children.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Child; Fet | 1997 |
Complications of sickle cell anemia in adults: guidelines for effective management.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Brain Diseases; Chest Pain; Child; Child, Preschool; | 1999 |
Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Bacteremia; Blood Group Antigens; Blood Substitutes; B | 2001 |
5 trials available for hydroxyurea and Acute Hemolytic Transfusion Reaction
| Article | Year |
|---|---|
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelat | 2013 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therap | 2013 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Pre | 2015 |
Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Female; Ferritins; Humans; Hydroxyurea; Iron; Iron | 2016 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
15 other studies available for hydroxyurea and Acute Hemolytic Transfusion Reaction
| Article | Year |
|---|---|
Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia.
Topics: beta-Thalassemia; Blood Transfusion; Child; Combined Modality Therapy; Female; Humans; Hydroxyurea; | 2022 |
SCAR: The high-prevalence antigen 013.008 in the Scianna blood group system.
Topics: Alleles; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Group Antigens; Blood Tra | 2021 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Child; Child, Preschool; Combined Modality Therapy | 2014 |
Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Vessels; Case-Control | 2014 |
Extramedullary hematopoiesis with spinal cord compression in a child with thalassemia intermedia.
Topics: beta-Thalassemia; Blood Group Antigens; Child; Combined Modality Therapy; Contraindications; Cytotox | 2009 |
Low cobalamin levels associated with sickle cell disease: Contrasting origins and clinical meanings in two instructive patients.
Topics: Adult; Anemia, Pernicious; Anemia, Sickle Cell; Autoantibodies; Depression; Female; Folic Acid; Gast | 2010 |
Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Cohort Studies; Combined Modalit | 2011 |
Impact of hydroxyurea on perioperative management and outcomes in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Child; Female; Humans; Hydroxyurea; Male; Perioperative Care; Retrospective Stu | 2011 |
Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Topics: Adolescent; Adult; Antimetabolites; beta-Globins; beta-Thalassemia; Child; Child, Preschool; Dose-Re | 2012 |
Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Infarction; Cerebral Re | 2013 |
[Diagnostic image (117). A man with frequent blood transfusion and blister on his fingers. A form of porpheria cutanea tarda caused by excess iron].
Topics: Aged; Blister; Diagnosis, Differential; Enzyme Inhibitors; Humans; Hydroxyurea; Iron Chelating Agent | 2002 |
Expanding the role of hydroxyurea in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Stroke; Transfusion Reaction; | 2004 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical | 2005 |
Megakaryocyte size and ploidy in thrombocytopenic or megakaryocytopenic mice.
Topics: Anemia; Animals; Blood Platelets; Hydroxyurea; Immune Sera; Megakaryocytes; Mice; Mice, Mutant Strai | 1990 |